|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of ACHE protein] |
CTD |
PMID:31077737 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
[acanthoside B co-treated with Scopolamine] results in increased expression of BDNF protein |
CTD |
PMID:31077737 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in decreased activity of CAT protein] |
CTD |
PMID:31077737 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:31077737 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in decreased expression of IL10 protein] |
CTD |
PMID:31077737 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of IL1B protein] |
CTD |
PMID:31077737 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of IL6 protein] |
CTD |
PMID:31077737 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of NOS2 protein] |
CTD |
PMID:31077737 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[acanthoside B co-treated with Scopolamine] results in increased phosphorylation of NTRK2 protein |
CTD |
PMID:31077737 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of PTGS2 protein] |
CTD |
PMID:31077737 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of TNF protein] |
CTD |
PMID:31077737 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
ginsenoside Rh1 results in decreased expression of IL4 |
CTD |
PMID:22855946 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
ginsenoside Rh1 results in decreased activity of JUN protein |
CTD |
PMID:22855946 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Rh1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]; ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG protein] |
CTD |
PMID:32623698 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases response to substance |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA] ginsenoside Rh1 results in decreased expression of TNF ginsenoside Rh1 results in decreased susceptibility to TNF protein |
CTD |
PMID:16557482 PMID:21875580 PMID:22855946 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:32762018 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of BAX protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of BCL2 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases cleavage decreases expression |
ISO |
ginsenoside Rh2 results in increased cleavage of CASP3 protein ginsenoside Rh2 results in decreased expression of CASP3 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CASP9 protein |
CTD |
PMID:32762018 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CCND1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC2 protein |
CTD |
PMID:26482938 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC6 protein |
CTD |
PMID:26482938 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation increases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK1 protein ginsenoside Rh2 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation increases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK3 protein ginsenoside Rh2 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MTOR protein |
CTD |
PMID:32762018 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of NFKBIA protein |
CTD |
PMID:32762018 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside Rh2 results in increased expression of and results in decreased phosphorylation of RELA protein |
CTD |
PMID:32762018 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:36457260 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] |
CTD |
PMID:36457260 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Hpse |
heparanase |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein] Amygdalin inhibits the reaction [Ovalbumin results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein] |
CTD |
PMID:36457260 |
|
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA] |
CTD |
PMID:33149750 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33149750 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased secretion of TGFB1 protein] Amygdalin inhibits the reaction [Ovalbumin results in increased secretion of TGFB1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased secretion of TGFB1 protein] |
CTD |
PMID:36457260 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] |
CTD |
PMID:36457260 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Gaa |
alpha glucosidase |
multiple interactions increases metabolic processing |
ISO |
GAA gene SNP inhibits the reaction [GAA protein results in increased metabolism of 4-methylumbelliferyl glucoside] |
CTD |
PMID:21963784 |
|
NCBI chr10:104,529,673...104,546,836
Ensembl chr10:104,529,747...104,546,836
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
albiflorin inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:37523837 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Drd2 |
dopamine receptor D2 |
affects expression |
EXP |
albiflorin affects the expression of DRD2 |
CTD |
PMID:26475043 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
albiflorin inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased phosphorylation of EGFR protein] |
CTD |
PMID:37523837 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
affects expression |
EXP |
albiflorin affects the expression of HTR1A |
CTD |
PMID:26475043 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects expression |
EXP |
albiflorin affects the expression of HTR2A |
CTD |
PMID:26475043 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
multiple interactions |
ISO |
Albiflorin inhibits the reaction [oxidized LDL increases phosphorylation of MAP3K7 protein in umbilical vein endothelial cells] |
RGD |
PMID:35601145 |
RGD:155804296 |
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
affects expression |
EXP |
albiflorin affects the expression of SLC6A3 |
CTD |
PMID:26475043 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Th |
tyrosine hydroxylase |
affects expression |
EXP |
albiflorin affects the expression of TH |
CTD |
PMID:26475043 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression |
EXP |
Amikacin results in decreased expression of ABCC3 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases expression |
EXP |
Amikacin results in decreased expression of ABCC4 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Casr |
calcium-sensing receptor |
increases activity |
ISO |
Amikacin results in increased activity of CASR protein |
CTD |
PMID:19884751 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
ISO |
Amikacin results in decreased activity of CAT protein cefepime inhibits the reaction [Amikacin results in decreased activity of CAT protein] |
CTD |
PMID:18781908 PMID:23416261 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Amikacin results in decreased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Amikacin results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
decreases expression |
ISO |
Amikacin results in decreased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
Amikacin results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Amikacin results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Amikacin results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
Amikacin results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Amikacin results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Tyr |
tyrosinase |
decreases activity |
ISO |
Amikacin results in decreased activity of TYR protein |
CTD |
PMID:23416261 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
|
G |
Gypa |
glycophorin A |
increases expression |
ISO |
apigetrin results in increased expression of GYPA protein |
CTD |
PMID:25058688 |
|
NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
asperuloside promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; dorsomorphin inhibits the reaction [asperuloside promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]] |
CTD |
PMID:38348709 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of CSF2 protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of CSF2 protein]] |
CTD |
PMID:38348709 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]] |
CTD |
PMID:38348709 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with asperuloside] results in increased expression of HMOX1 protein; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein] |
CTD |
PMID:33974900 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein] |
CTD |
PMID:33974900 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 protein] |
CTD |
PMID:33974900 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions |
ISO |
asperuloside inhibits the reaction [[dorsomorphin co-treated with Cyclophosphamide] results in decreased expression of KIT protein]; asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of KIT protein] |
CTD |
PMID:38348709 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
asperuloside promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]; dorsomorphin inhibits the reaction [asperuloside promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]] |
CTD |
PMID:38348709 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] |
CTD |
PMID:33974900 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; asperuloside inhibits the reaction [dorsomorphin promotes the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]] |
CTD |
PMID:38348709 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
ISO |
[asperuloside co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; [lipopolysaccharide, E coli O55-B5 co-treated with asperuloside] results in increased expression of NFE2L2 protein; asperuloside affects the reaction [NFE2L2 protein affects the expression of NQO1 mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of NFE2L2 protein] asperuloside affects the localization of NFE2L2 protein |
CTD |
PMID:33974900 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
asperuloside affects the reaction [NFE2L2 protein affects the expression of NQO1 mRNA] |
CTD |
PMID:33974900 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
asperuloside promotes the reaction [Cyclophosphamide results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:38348709 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein] |
CTD |
PMID:33974900 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Thpo |
thrombopoietin |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]] |
CTD |
PMID:38348709 |
|
Ensembl chr11:80,182,820...80,188,167
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; asperuloside inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:16508180 PMID:33974900 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein] calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA; calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein |
CTD |
PMID:36812960 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein] calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA; calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein |
CTD |
PMID:36812960 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of CASP3 mRNA] |
CTD |
PMID:36812960 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in decreased expression of CAT protein |
CTD |
PMID:36812960 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Epo |
erythropoietin |
increases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in increased expression of EPO mRNA |
CTD |
PMID:21309574 PMID:37348668 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
decreases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in decreased expression of GPT protein |
CTD |
PMID:36812960 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in decreased degradation of and results in increased expression of HIF1A protein modified form; calycosin-7-O-beta-D-glucoside results in increased expression of and results in decreased degradation of HIF1A protein calycosin-7-O-beta-D-glucoside results in increased expression of HIF1A mRNA; calycosin-7-O-beta-D-glucoside results in increased expression of HIF1A protein |
CTD |
PMID:21309574 PMID:37348668 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions decreases expression |
ISO |
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of CASP3 mRNA] calycosin-7-O-beta-D-glucoside results in decreased expression of TXN protein calycosin-7-O-beta-D-glucoside results in decreased expression of TXN mRNA; calycosin-7-O-beta-D-glucoside results in decreased expression of TXN protein |
CTD |
PMID:36812960 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Ache |
acetylcholinesterase |
increases expression multiple interactions |
EXP |
daidzin results in increased expression of ACHE mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of ACHE mRNA]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of and results in increased activity of ACHE protein]; daidzin results in increased expression of and results in increased activity of ACHE protein |
CTD |
PMID:31034797 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
daidzin inhibits the reaction [ALDH2 protein results in increased hydrolysis of 4-nitrophenyl acetate]; daidzin inhibits the reaction [ALDH2 protein results in increased oxidation of propionaldehyde] |
CTD |
PMID:21349255 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:104,259,992...104,292,168
Ensembl chr 4:104,259,992...104,292,168
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased expression of BDNF protein] |
CTD |
PMID:32450180 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Cabp5 |
calcium binding protein 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:74,350,811...74,363,830
Ensembl chr 1:74,350,811...74,363,830
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased activity of CAT protein] |
CTD |
PMID:32450180 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd200r1 |
CD200 receptor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr11:55,886,937...55,921,217
Ensembl chr11:55,887,717...55,921,285
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:33,261,622...33,337,028
Ensembl chr12:33,261,476...33,293,932
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:55,934,874...55,962,132
Ensembl chr 3:55,934,874...55,962,108
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Dennd2d |
DENN domain containing 2D |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:193,973,231...193,992,275
Ensembl chr 2:193,973,231...193,992,270
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dpp9 |
dipeptidyl peptidase 9 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:1,011,347...1,046,337
Ensembl chr 9:1,011,351...1,046,541
|
|
G |
Edrf1 |
erythroid differentiation regulatory factor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:188,441,514...188,478,743
Ensembl chr 1:188,441,634...188,478,701
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fam171a2 |
family with sequence similarity 171, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:87,393,888...87,404,051
Ensembl chr10:87,394,007...87,404,053
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:63,992,867...64,008,047
Ensembl chr 4:63,992,867...64,008,047
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397
|
|
G |
Fam241b |
family with sequence similarity 241 member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
|
|
G |
Fgd6 |
FYVE, RhoGEF and PH domain containing 6 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:28,597,609...28,712,908
Ensembl chr 7:28,597,609...28,712,456
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
daidzin results in increased expression of FOS mRNA |
CTD |
PMID:17142977 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513
|
|
G |
Hipk4 |
homeodomain interacting protein kinase 4 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:82,810,708...82,821,080
Ensembl chr 1:82,810,708...82,821,077
|
|
G |
Hmcn1 |
hemicentin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:62,615,461...63,084,524
Ensembl chr13:62,615,461...63,084,524
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased expression of HMOX1 protein] |
CTD |
PMID:32450180 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Il6r |
interleukin 6 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
|
|
G |
Kdm5a |
lysine demethylase 5A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:153,565,909...153,643,912
Ensembl chr 4:153,565,846...153,642,422
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Ldlrap1 |
low density lipoprotein receptor adaptor protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:146,955,607...146,978,601
Ensembl chr 5:146,955,607...146,978,601
|
|
G |
Lmod1 |
leiomodin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813
|
|
G |
Lsr |
lipolysis stimulated lipoprotein receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:86,185,769...86,201,952
Ensembl chr 1:86,186,431...86,201,952
|
|
G |
Mrpl33 |
mitochondrial ribosomal protein L33 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:24,825,800...24,833,994
Ensembl chr 6:24,825,827...24,833,834
|
|
G |
Mtmr11 |
myotubularin related protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:183,721,983...183,732,148
Ensembl chr 2:183,723,530...183,732,148
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Nefh |
neurofilament heavy chain |
increases expression |
EXP |
daidzin results in increased expression of NEFH mRNA; daidzin results in increased expression of NEFH protein |
CTD |
PMID:31034797 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
increases expression |
EXP |
daidzin results in increased expression of NEFL mRNA; daidzin results in increased expression of NEFL protein |
CTD |
PMID:31034797 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:28964809 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
daidzin results in increased expression of PGR protein |
CTD |
PMID:17142977 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression multiple interactions |
EXP |
daidzin results in increased expression of PRIMA1 mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of PRIMA1 mRNA] |
CTD |
PMID:31034797 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA |
CTD |
PMID:27424125 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prpf40a |
pre-mRNA processing factor 40 homolog A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:37,625,585...37,689,859
Ensembl chr 3:37,627,690...37,690,886
|
|
G |
Pspc1 |
paraspeckle component 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:30,828,617...30,911,315
Ensembl chr15:30,828,626...30,911,202
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:42,637,513...42,703,024
Ensembl chr13:42,637,549...42,703,024
|
|
G |
Rgs22 |
regulator of G-protein signaling 22 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:67,188,531...67,308,805
Ensembl chr 7:67,188,519...67,308,875
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
|
|
G |
Selplg |
selectin P ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:42,796,690...42,809,908
Ensembl chr12:42,796,580...42,812,585
|
|
G |
Siglec10 |
sialic acid binding Ig-like lectin 10 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:93,817,301...93,826,376
Ensembl chr 1:93,817,335...93,825,931
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Snx30 |
sorting nexin family member 30 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:74,683,902...74,813,013
Ensembl chr 5:74,684,015...74,792,631
|
|
G |
Ssc5d |
scavenger receptor cysteine rich family member with 5 domains |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:68,891,942...68,910,462
Ensembl chr 1:68,891,949...68,909,743
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein |
CTD |
PMID:28964809 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326
|
|
G |
Tp53i11 |
tumor protein p53 inducible protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050
|
|
G |
Vcpip1 |
valosin containing protein interacting protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:9,534,247...9,560,889
Ensembl chr 5:9,534,129...9,562,040
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
daidzin inhibits the reaction [Pentylenetetrazole results in increased expression of VEGFA protein] |
CTD |
PMID:32450180 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance multiple interactions increases expression |
ISO |
ABCB1 exon polymorphism affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Celecoxib results in decreased expression of ABCB1] which results in increased susceptibility to Etoposide Etoposide results in increased expression of ABCB1 mRNA; Etoposide results in increased expression of ABCB1 protein |
CTD |
PMID:12969965 PMID:15239124 PMID:19047049 PMID:19562670 PMID:27570640 PMID:27840903 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects response to substance decreases response to substance multiple interactions decreases uptake increases expression |
ISO |
ABCC1 protein affects the susceptibility to Etoposide ABCC1 protein results in decreased susceptibility to Etoposide; ABCC1 results in decreased susceptibility to Etoposide [GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; hesperetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; naringenin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Silymarin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Tocopherols inhibits the reaction [ABCC1 protein affects the export of Etoposide]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide] ABCC1 protein results in decreased uptake of Etoposide Etoposide results in increased expression of ABCC1 mRNA Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide] |
CTD |
PMID:7954421 PMID:8968083 PMID:9334814 PMID:10348353 PMID:10856430 PMID:10900222 PMID:11778547 PMID:15180633 PMID:15460906 PMID:15617835 PMID:15999103 PMID:16156793 PMID:16217747 More...
|
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects transport multiple interactions |
ISO |
ABCC2 protein affects the transport of Etoposide Probenecid promotes the reaction [ABCC2 protein affects the transport of Etoposide] |
CTD |
PMID:15751272 PMID:15849751 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases response to substance |
ISO |
ABCC3 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15884115 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] |
CTD |
PMID:21712253 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abhd4 |
abhydrolase domain containing 4, N-acyl phospholipase B |
increases expression |
ISO |
Etoposide results in increased expression of ABHD4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:27,697,384...27,716,013
Ensembl chr15:27,704,113...27,716,966
|
|
G |
Abra |
actin-binding Rho activating protein |
increases expression |
ISO |
Etoposide results in increased expression of ABRA mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:72,970,187...72,974,255
Ensembl chr 7:72,970,186...72,974,255
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
affects response to substance |
ISO |
ACADM protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression decreases expression |
ISO EXP |
Etoposide results in increased expression of ACE2 mRNA Etoposide results in decreased expression of ACE2 mRNA |
CTD |
PMID:29397400 PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Aco1 |
aconitase 1 |
increases expression |
ISO |
Etoposide results in increased expression of ACO1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
affects response to substance |
ISO |
ACSL3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
ISO |
Etoposide results in decreased expression of ACTA1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Agrn |
agrin |
increases expression |
ISO |
Etoposide results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
affects response to substance |
ISO |
AHCYL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
increases expression |
ISO |
Etoposide results in increased expression of AHI1 protein alternative form |
CTD |
PMID:19379585 |
|
NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
affects response to substance |
ISO |
AKAP12 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases response to substance increases phosphorylation multiple interactions |
ISO |
AKT1 protein modified form results in increased susceptibility to Etoposide Etoposide results in increased phosphorylation of AKT1 protein Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein]; pepstatin inhibits the reaction [AKT1 protein modified form results in increased susceptibility to Etoposide]; PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:17699715 PMID:17935137 PMID:23396362 PMID:27769712 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:19162187 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
Etoposide results in increased expression of ALAS1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of ALDH1A1 mRNA; Etoposide results in increased expression of ALDH1A1 protein FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein] |
CTD |
PMID:33969609 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
affects response to substance |
ISO |
ALDH3A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:15905174 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
affects response to substance multiple interactions |
ISO |
ALDOC protein affects the susceptibility to Etoposide [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ALDOC protein |
CTD |
PMID:16217747 PMID:29733421 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alpg |
alkaline phosphatase, germ cell |
affects response to substance |
ISO |
ALPG protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:87,748,721...87,761,500
Ensembl chr 9:87,753,648...87,757,836
|
|
G |
Alpp |
alkaline phosphatase, placental |
affects response to substance |
ISO |
ALPP protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Ank1 |
ankyrin 1 |
increases expression |
ISO |
Etoposide results in increased expression of ANK1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:68,876,294...69,054,963
Ensembl chr16:68,877,504...69,054,759
|
|
G |
Ankrd10 |
ankyrin repeat domain 10 |
decreases expression |
ISO |
Etoposide results in decreased expression of ANKRD10 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr16:77,866,489...77,889,745
Ensembl chr16:77,864,261...77,889,745
|
|
G |
Ankrd27 |
ankyrin repeat domain 27 |
decreases expression |
ISO |
Etoposide results in decreased expression of ANKRD27 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:88,251,216...88,303,615
Ensembl chr 1:88,251,226...88,303,615
|
|
G |
Ankrd28 |
ankyrin repeat domain 28 |
affects response to substance |
ISO |
ANKRD28 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:6,918,487...7,050,244
Ensembl chr16:6,914,336...7,050,249
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Etoposide results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa7 |
annexin A7 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ANXA7 protein |
CTD |
PMID:29733421 |
|
NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
Etoposide results in increased expression of APAF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases response to substance |
ISO |
APEX1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:20856196 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Aplp1 |
amyloid beta precursor like protein 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of APLP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:85,696,880...85,707,215
Ensembl chr 1:85,696,882...85,707,155
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of AQP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Ar |
androgen receptor |
multiple interactions increases degradation |
ISO |
calpain inhibitor 2 inhibits the reaction [Etoposide results in increased degradation of AR protein]; CAST inhibits the reaction [Etoposide results in increased degradation of AR protein]; Etoposide inhibits the reaction [Androgens results in increased activity of AR protein]; Etoposide inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18726991 PMID:28377212 PMID:30818834 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Areg |
amphiregulin |
increases expression decreases expression |
ISO |
Etoposide results in increased expression of AREG mRNA; Etoposide results in increased expression of AREG protein Etoposide results in decreased expression of AREG mRNA |
CTD |
PMID:15228094 PMID:25270620 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg2 |
arginase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ARG2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression |
ISO |
Etoposide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arih1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
increases response to substance |
ISO |
ARIH1 mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:25624349 |
|
NCBI chr 8:59,777,378...59,879,762
Ensembl chr 8:59,777,379...59,880,245
|
|
G |
Arl6ip5 |
ADP-ribosylation factor like GTPase 6 interacting protein 5 |
increases response to substance decreases expression |
ISO |
ARL6IP5 protein results in increased susceptibility to Etoposide Etoposide results in decreased expression of ARL6IP5 |
CTD |
PMID:19492242 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:33969609 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arsa |
arylsulfatase A |
decreases expression |
ISO |
Etoposide results in decreased expression of ARSA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:120,542,788...120,547,577
Ensembl chr 7:120,543,362...120,548,783
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
affects response to substance |
ISO |
ASAH1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions |
ISO |
Etoposide results in increased phosphorylation of and results in increased activity of ATF2 protein |
CTD |
PMID:12663670 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of and results in increased activity of ATM protein Etoposide results in increased phosphorylation of ATM protein Etoposide results in increased phosphorylation of and affects the localization of ATM protein; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of and affects the localization of ATM protein] |
CTD |
PMID:22242153 PMID:26259609 PMID:37451322 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp13a4 |
ATPase 13A4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP13A4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
affects response to substance |
ISO |
ATP1A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atp1b4 |
ATPase Na+/K+ transporting family member beta 4 |
increases expression |
ISO |
Etoposide results in increased expression of ATP1B4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr X:117,087,284...117,108,023
Ensembl chr X:117,057,423...117,108,020
|
|
G |
Atp5me |
ATP synthase membrane subunit e |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of ATP5ME protein |
CTD |
PMID:29733421 |
|
NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP5PO protein |
CTD |
PMID:29733421 |
|
NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592
|
|
G |
Atp6v0a4 |
ATPase H+ transporting V0 subunit a4 |
affects response to substance |
ISO |
ATP6V0A4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
multiple interactions decreases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ATP6V1A protein Etoposide results in decreased expression of ATP6V1A protein |
CTD |
PMID:29733421 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atp7a |
ATPase copper transporting alpha |
decreases response to substance |
ISO |
ATP7A protein results in decreased susceptibility to Etoposide |
CTD |
PMID:17510416 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atr |
ATR serine/threonine kinase |
increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of ATR protein |
CTD |
PMID:22242153 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Atxn1 |
ataxin 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATXN1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
Etoposide results in decreased expression of AURKA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
affects response to substance |
ISO |
AVPI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
increases expression |
ISO |
Etoposide results in increased expression of AVPR1A mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Etoposide results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bace2 |
beta-secretase 2 |
affects response to substance |
ISO |
BACE2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bag2 |
BAG cochaperone 2 |
affects response to substance |
ISO |
BAG2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases activity increases response to substance affects response to substance multiple interactions affects expression |
ISO |
Etoposide results in increased activity of BAK1 protein BAK1 protein results in increased susceptibility to Etoposide BAK1 protein affects the susceptibility to Etoposide nimesulide inhibits the reaction [Etoposide results in increased activity of BAK1 protein] Etoposide affects the expression of BAK1 protein |
CTD |
PMID:15215046 PMID:16077961 PMID:17688235 PMID:21745461 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
affects response to substance |
ISO |
BAMBI protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression decreases folding affects response to substance |
ISO |
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [Cisplatin co-treated with Etoposide] affects the localization of BAX protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BAX protein; [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]; Etoposide results in increased activity of and affects the localization of BAX protein; Etoposide results in increased cleavage of and results in increased expression of BAX protein; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] affects the localization of BAX protein]; nimesulide inhibits the reaction [Etoposide results in increased activity of and affects the localization of BAX protein] Etoposide results in increased expression of BAX mRNA; Etoposide results in increased expression of BAX protein BAX protein affects the susceptibility to Etoposide |
CTD |
PMID:9815696 PMID:10620629 PMID:15131059 PMID:16077961 PMID:16120219 PMID:18676776 PMID:21527772 PMID:21745461 PMID:21880625 PMID:29397400 PMID:33148531 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions affects response to substance |
ISO |
Etoposide results in increased expression of BBC3 mRNA; Etoposide results in increased expression of BBC3 protein entinostat promotes the reaction [Etoposide results in increased expression of BBC3 protein]; Etoposide promotes the reaction [entinostat results in increased expression of BBC3 protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of BBC3 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of BBC3 protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of BBC3 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of BBC3 protein] BBC3 protein affects the susceptibility to Etoposide |
CTD |
PMID:20477944 PMID:21801448 PMID:25699604 PMID:37956312 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of BCL2 mRNA; Etoposide results in decreased expression of BCL2 protein [G(M3) Ganglioside results in increased expression of BCL2 protein] which results in decreased susceptibility to Etoposide; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 mRNA]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 protein] |
CTD |
PMID:8840993 PMID:9815696 PMID:12063570 PMID:15917659 PMID:16571667 PMID:19408126 PMID:33148531 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions affects expression decreases response to substance |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein] Etoposide affects the expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:8840993 PMID:10620629 PMID:11468182 PMID:15215046 PMID:15917659 PMID:19047049 More...
|
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
decreases response to substance |
ISO |
BCL2L2 results in decreased susceptibility to Etoposide |
CTD |
PMID:14973057 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of BCL6B mRNA |
CTD |
PMID:29733421 |
|
NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of BDNF mRNA HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA] |
CTD |
PMID:20573984 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases expression increases cleavage |
ISO |
CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Estradiol inhibits the reaction [Etoposide results in increased expression of BID mRNA] |
CTD |
PMID:19426747 PMID:21801448 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bik |
BCL2-interacting killer |
increases response to substance |
ISO |
BIK protein results in increased susceptibility to Etoposide |
CTD |
PMID:16007125 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bin1 |
bridging integrator 1 |
increases response to substance |
ISO |
BIN1 protein results in increased susceptibility to Etoposide |
CTD |
PMID:21447800 |
|
NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263
|
|
G |
Bin3 |
bridging integrator 3 |
affects response to substance |
ISO |
BIN3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:45,173,725...45,212,607
Ensembl chr15:45,173,732...45,212,604
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
affects response to substance decreases response to substance increases expression |
ISO |
BIRC2 protein affects the susceptibility to Etoposide BIRC2 protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of BIRC2 mRNA |
CTD |
PMID:10815900 PMID:14970392 PMID:15050749 PMID:16217747 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases response to substance decreases expression multiple interactions |
ISO |
BIRC3 protein results in decreased susceptibility to Etoposide Etoposide results in decreased expression of BIRC3 mRNA [Etoposide co-treated with KN 62] results in decreased expression of BIRC3 protein |
CTD |
PMID:14666661 PMID:15050749 PMID:16120219 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases response to substance increases expression |
ISO |
[FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; BIRC5 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Estradiol inhibits the reaction [Etoposide results in increased expression of BIRC5 mRNA] BIRC5 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15917659 PMID:16322251 PMID:16364925 PMID:16382892 PMID:19211844 PMID:19426747 More...
|
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
decreases response to substance |
ISO |
BIRC7 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:17437058 |
|
NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606
|
|
G |
Blm |
BLM RecQ like helicase |
decreases expression |
ISO |
Etoposide results in decreased expression of BLM mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions increases expression decreases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein]; pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of BRCA1 protein] Etoposide results in increased expression of BRCA1 protein Etoposide results in decreased expression of BRCA1 mRNA |
CTD |
PMID:15607317 PMID:16417649 PMID:26259609 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Etoposide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 PMID:25270620 |
|
NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
multiple interactions increases expression |
ISO |
TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein] Etoposide results in increased expression of BTG2 mRNA; Etoposide results in increased expression of BTG2 protein |
CTD |
PMID:21382384 PMID:22003191 PMID:24211769 PMID:27358234 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of BTG3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
Etoposide results in decreased expression of BUB1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
decreases expression |
ISO |
Etoposide results in decreased expression of BUB1B mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C14h4orf19 |
similar to human chromosome 4 open reading frame 19 |
affects response to substance |
ISO |
C4ORF19 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,387,393...44,478,041
|
|
G |
C1qbp |
complement C1q binding protein |
decreases response to substance |
ISO |
C1QBP protein results in decreased susceptibility to Etoposide |
CTD |
PMID:25354864 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
C2h5orf22 |
similar to human chromosome 5 open reading frame 22 |
affects response to substance |
ISO |
C5ORF22 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:61,848,790...61,864,762
Ensembl chr 2:61,849,363...61,864,738
|
|
G |
Cab39 |
calcium binding protein 39 |
decreases expression |
ISO |
Etoposide results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Cadps2 |
calcium dependent secretion activator 2 |
affects response to substance |
ISO |
CADPS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:51,780,415...52,309,641
Ensembl chr 4:51,781,053...52,309,829
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions decreases response to substance |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CALCA protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:16222118 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calm1 |
calmodulin 1 |
increases expression |
ISO |
Etoposide results in increased expression of CALM1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Card10 |
caspase recruitment domain family, member 10 |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of CARD10 mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:110,330,408...110,359,224
|
|
G |
Casp2 |
caspase 2 |
increases expression increases splicing |
ISO |
Etoposide results in increased expression of CASP2 mRNA alternative form Etoposide results in increased splicing of CASP2 mRNA |
CTD |
PMID:14757846 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
affects expression increases cleavage multiple interactions increases activity increases expression |
ISO EXP |
Etoposide affects the expression of CASP3 protein Etoposide results in increased cleavage of CASP3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [Etoposide co-treated with Mifepristone] results in increased activity of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; Dehydroascorbic Acid promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Etoposide promotes the reaction [Gold results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Nanotubes, Carbon results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Silver results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased expression of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased cleavage of CASP3 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein] Etoposide results in increased expression of CASP3 protein; Etoposide results in increased expression of CASP3 protein modified form [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of CASP3 protein 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Metoclopramide inhibits the reaction [Etoposide results in increased activity of CASP3 protein] |
CTD |
PMID:8840993 PMID:10759716 PMID:12871656 PMID:15215046 PMID:15924153 PMID:16014620 PMID:16192531 PMID:16364925 PMID:16545138 PMID:16844113 PMID:16951922 PMID:17516866 PMID:17935137 PMID:18056177 PMID:18649362 PMID:19047049 PMID:19408126 PMID:19662097 PMID:19760634 PMID:20299546 PMID:20573984 PMID:21617849 PMID:21745461 PMID:21745629 PMID:21801448 PMID:21880625 PMID:22275372 PMID:22302033 PMID:23144690 PMID:25447644 PMID:26259609 PMID:29027213 PMID:30217652 PMID:30890322 PMID:33148531 PMID:35065218 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
[STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP7 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein] 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased activity of CASP7 protein] |
CTD |
PMID:18056177 PMID:18649362 PMID:20299546 PMID:21801448 PMID:22275372 PMID:22302033 PMID:26259609 More...
|
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases response to substance increases cleavage increases activity decreases response to substance |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; acetyl-leucyl-glutamyl-histidyl-aspartal inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP8 protein; Etoposide results in increased expression of and results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP8 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein] CASP8 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15475000 PMID:21745461 PMID:21801448 PMID:22010212 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage increases activity affects expression |
ISO |
[CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Etoposide results in increased cleavage of and results in increased activity of CASP9 protein; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] Etoposide affects the expression of CASP9 protein |
CTD |
PMID:12925536 PMID:15215046 PMID:16364925 PMID:16799960 PMID:17935137 PMID:18056177 PMID:18676776 PMID:21324178 PMID:21745461 PMID:21801448 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casq2 |
calsequestrin 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of CASQ2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:189,526,003...189,582,276
Ensembl chr 2:189,525,960...189,582,267
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
CAST inhibits the reaction [Etoposide results in increased degradation of AR protein] |
CTD |
PMID:18726991 |
|
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cat |
catalase |
increases response to substance multiple interactions increases activity |
ISO EXP |
CAT results in increased susceptibility to Etoposide EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein] |
CTD |
PMID:21689642 PMID:25451571 PMID:29069929 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc51 |
coiled-coil domain containing 51 |
decreases expression |
ISO |
Etoposide results in decreased expression of CCDC51 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 8:109,722,595...109,741,478
Ensembl chr 8:109,722,557...109,741,472
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
increases response to substance decreases response to substance |
ISO |
CCDC6 results in increased susceptibility to Etoposide CCDC6 results in decreased susceptibility to Etoposide |
CTD |
PMID:22363533 PMID:22655027 |
|
NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
Etoposide results in increased expression of CCL3 protein |
CTD |
PMID:10540334 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
Etoposide results in increased expression of CCN2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
Etoposide affects the expression of and affects the localization of CCNA2 protein Etoposide results in decreased expression of CCNA2 mRNA; Etoposide results in decreased expression of CCNA2 protein |
CTD |
PMID:16120219 PMID:17390037 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CCNB1 mRNA; Etoposide results in decreased expression of CCNB1 protein |
CTD |
PMID:16120219 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Etoposide results in increased expression of CCND1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
ISO |
Etoposide results in increased expression of CCNG1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Etoposide results in increased expression of CCNG2 mRNA |
CTD |
PMID:18754885 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
Etoposide results in increased expression of CCS mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of CCT8 protein |
CTD |
PMID:29733421 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Etoposide results in increased expression of CD274 protein |
CTD |
PMID:17920123 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions decreases response to substance |
ISO |
CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] CD40LG protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16545138 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd44 |
CD44 molecule |
affects response to substance multiple interactions |
ISO |
CD44 protein affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:15215046 PMID:19047049 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
affects response to substance |
ISO |
CD55 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd59b |
CD59b molecule |
multiple interactions |
ISO |
[Cisplatin co-treated with Etoposide] results in decreased expression of CD59 protein |
CTD |
PMID:21826740 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC25A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC25C mRNA |
CTD |
PMID:16120219 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc42bpg |
CDC42 binding protein kinase gamma |
increases expression |
ISO |
Etoposide results in increased expression of CDC42BPG mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:203,608,339...203,628,502
Ensembl chr 1:203,608,574...203,628,502
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC45 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC6 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases expression affects response to substance |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein] CDK2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 PMID:16417649 PMID:20149834 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; entinostat promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [entinostat results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of CDKN1A protein]; KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of CDKN1A protein] Etoposide results in increased expression of CDKN1A mRNA; Etoposide results in increased expression of CDKN1A protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; Etoposide promotes the reaction [Niacin deficiency results in increased expression of CDKN1A protein]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:14601052 PMID:16120219 PMID:16882877 PMID:17516866 PMID:21212465 PMID:21526190 PMID:21527772 PMID:21617849 PMID:21801448 PMID:21880625 PMID:23690541 PMID:24067374 PMID:24211769 PMID:25078064 PMID:25699604 PMID:25914138 PMID:26055805 PMID:27129209 PMID:27358234 PMID:27982581 PMID:29471073 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of CDKN1B protein wortmannin promotes the reaction [Etoposide results in increased expression of CDKN1B protein] |
CTD |
PMID:17935137 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression multiple interactions |
EXP ISO |
Etoposide results in increased expression of CDKN2A mRNA [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA] |
CTD |
PMID:21526190 PMID:23690541 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDKN3 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Etoposide results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression increases degradation |
ISO |
Etoposide results in decreased expression of CEBPA mRNA; Etoposide results in decreased expression of CEBPA protein Etoposide results in increased degradation of CEBPA protein |
CTD |
PMID:19662097 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
Etoposide results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
Etoposide results in increased expression of CEL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
Etoposide results in decreased expression of CENPF mRNA |
CTD |
PMID:16120219 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cercam |
cerebral endothelial cell adhesion molecule |
increases expression |
ISO |
Etoposide results in increased expression of CERCAM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
Etoposide results in increased expression of CES1D mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2e |
carboxylesterase 2E |
increases expression |
ISO |
Etoposide results in increased expression of CES2E mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression |
ISO |
Etoposide results in increased expression of CFLAR protein |
CTD |
PMID:14601052 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
increases expression |
ISO |
Etoposide results in increased expression of CGREF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CHAC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
decreases expression |
ISO |
Etoposide results in decreased expression of CHAF1A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chek1 |
checkpoint kinase 1 |
affects response to substance multiple interactions |
ISO |
CHEK1 protein affects the susceptibility to Etoposide TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide] |
CTD |
PMID:18698031 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases phosphorylation multiple interactions |
ISO |
Etoposide results in increased phosphorylation of CHEK2 protein 4-fluoro-2-(4-(4-(2-hydroxypropan-2-yl)pyrrolidin-3-ylamino)-6,7-dimethoxyquinazolin-2-yl)phenol inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein]; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:21186793 PMID:22242153 PMID:26259609 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases response to substance |
ISO |
CHI3L1 results in decreased susceptibility to Etoposide |
CTD |
PMID:20506295 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases expression |
ISO |
Etoposide results in decreased expression of CHUK protein |
CTD |
PMID:30177839 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ciapin1 |
cytokine induced apoptosis inhibitor 1 |
decreases response to substance |
ISO |
CIAPIN1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18389626 |
|
NCBI chr19:10,179,963...10,195,511
Ensembl chr19:10,180,100...10,195,503
|
|
G |
Ckm |
creatine kinase, M-type |
decreases expression |
ISO |
Etoposide results in decreased expression of CKM mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Ckmt1 |
creatine kinase, mitochondrial 1 |
affects response to substance |
ISO |
CKMT1B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758
|
|
G |
Coa7 |
cytochrome c oxidase assembly factor 7 |
decreases expression |
ISO |
Etoposide results in decreased expression of COA7 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:123,069,356...123,080,942
Ensembl chr 5:123,069,371...123,080,199
|
|
G |
Cobl |
cordon-bleu WH2 repeat protein |
decreases expression |
ISO |
Etoposide results in decreased expression of COBL mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
affects response to substance |
ISO |
COL15A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
Etoposide results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col9a3 |
collagen type IX alpha 3 chain |
affects response to substance |
ISO |
COL9A3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
decreases expression |
ISO |
Etoposide results in decreased expression of COX6A2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cps1 |
carbamoyl-phosphate synthase 1 |
affects response to substance |
ISO |
CPS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of CPT2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
ISO |
Etoposide results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein; HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20573984 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crem |
cAMP responsive element modulator |
affects response to substance |
ISO |
CREM protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crip2 |
cysteine-rich protein 2 |
increases expression |
ISO |
Etoposide results in increased expression of CRIP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Csgalnact1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
affects response to substance |
ISO |
CSGALNACT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319
|
|
G |
Cth |
cystathionine gamma-lyase |
affects response to substance |
ISO |
CTH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Etoposide results in decreased expression of CXCL12 mRNA; Etoposide results in decreased expression of CXCL12 protein |
CTD |
PMID:22363485 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Etoposide affects the localization of CYCS protein |
CTD |
PMID:10759716 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of CYP1A1 mRNA; Etoposide results in increased expression of CYP1A1 protein Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein] |
CTD |
PMID:29471073 PMID:31542801 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
Etoposide results in increased expression of CYP1A2 mRNA |
CTD |
PMID:31542801 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
decreases response to substance |
ISO |
CYP26A1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15703382 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
increases expression |
ISO |
Etoposide results in increased expression of CYP27B1 mRNA |
CTD |
PMID:17716971 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases expression |
ISO |
Etoposide results in increased expression of CYP2C55 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases expression |
ISO |
Etoposide results in increased expression of CYP2C29 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CYP2S1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases methylation increases expression multiple interactions affects response to substance |
ISO |
CYP3A4 protein results in decreased methylation of Etoposide Etoposide results in increased expression of CYP3A4 mRNA [Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide] CYP3A4 gene polymorphism affects the susceptibility to Etoposide; CYP3A4 protein affects the susceptibility to Etoposide |
CTD |
PMID:8114683 PMID:12969965 PMID:17279585 PMID:25455453 PMID:31542801 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects response to substance decreases methylation |
ISO |
CYP3A5 gene polymorphism affects the susceptibility to Etoposide CYP3A5 protein results in decreased methylation of Etoposide |
CTD |
PMID:8114683 PMID:12969965 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyren |
cell cycle regulator of NHEJ |
affects localization |
ISO |
Etoposide affects the localization of CYREN protein alternative form |
CTD |
PMID:24610814 |
|
NCBI chr 4:63,547,311...63,553,394
Ensembl chr 4:63,547,335...63,551,602
|
|
G |
Dab2 |
DAB adaptor protein 2 |
affects response to substance |
ISO |
DAB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dapk1 |
death associated protein kinase 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of DAPK1 protein; Etoposide results in increased expression of DAPK1 protein modified form DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein] |
CTD |
PMID:30177839 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dbf4 |
DBF4-CDC7 kinase regulatory subunit |
decreases expression |
ISO |
Etoposide results in decreased expression of DBF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dbn1 |
drebrin 1 |
affects response to substance |
ISO |
DBN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dcaf4 |
DDB1 and CUL4 associated factor 4 |
increases expression |
ISO |
Etoposide results in increased expression of DCAF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982
|
|
G |
Dct |
dopachrome tautomerase |
affects response to substance |
ISO |
DCT protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects response to substance |
ISO |
DDIT4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
increases expression |
ISO |
Etoposide results in increased expression of DDR1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Des |
desmin |
decreases expression |
ISO |
Etoposide results in decreased expression of DES mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dkk3 |
dickkopf WNT signaling pathway inhibitor 3 |
affects response to substance |
ISO |
DKK3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:166,237,969...166,281,271
Ensembl chr 1:166,238,238...166,280,590
|
|
G |
Dmd |
dystrophin |
affects response to substance decreases expression |
ISO |
DMD protein affects the susceptibility to Etoposide Etoposide results in decreased expression of DMD mRNA |
CTD |
PMID:16217747 PMID:29397400 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dmrt1 |
doublesex and mab-3 related transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of DMRT1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:223,142,859...223,241,333
Ensembl chr 1:223,142,859...223,241,333
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases response to substance |
EXP ISO |
DNMT1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18314485 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases response to substance |
ISO |
DNMT3B protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18314485 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dpp7 |
dipeptidylpeptidase 7 |
multiple interactions |
ISO |
Etoposide promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline] |
CTD |
PMID:16725115 |
|
NCBI chr 3:8,165,091...8,169,343
Ensembl chr 3:8,165,091...8,169,355
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of DPYSL2 protein |
CTD |
PMID:29733421 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
ISO |
Etoposide results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
affects response to substance |
ISO |
DUSP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
affects response to substance increases expression |
ISO |
DUSP4 protein affects the susceptibility to Etoposide Etoposide results in increased expression of DUSP4 mRNA |
CTD |
PMID:16217747 PMID:29397400 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter] |
CTD |
PMID:19491197 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
decreases expression |
ISO |
Etoposide results in decreased expression of EDNRB mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Efs |
embryonal Fyn-associated substrate |
increases expression |
ISO |
Etoposide results in increased expression of EFS mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:28,392,417...28,403,016
Ensembl chr15:28,392,187...28,401,902
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide |
CTD |
PMID:16969495 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfl8 |
EGF-like-domain, multiple 8 |
affects response to substance |
ISO |
EGFL8 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:4,132,930...4,136,024
Ensembl chr20:4,133,629...4,136,018
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Etoposide results in decreased expression of EGFR mRNA; Etoposide results in decreased expression of EGFR protein |
CTD |
PMID:15228094 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
increases expression |
ISO |
Etoposide results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Eif2s2 |
eukaryotic translation initiation factor 2 subunit beta |
decreases expression |
ISO |
Etoposide results in decreased expression of EIF2S2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:143,374,652...143,395,460
Ensembl chr 3:143,373,686...143,395,432
|
|
G |
Eif3a |
eukaryotic translation initiation factor 3, subunit A |
increases response to substance |
ISO |
EIF3A results in increased susceptibility to Etoposide |
CTD |
PMID:21610145 |
|
NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Emp2 |
epithelial membrane protein 2 |
affects response to substance |
ISO |
EMP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
Etoposide results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
|
|
G |
En2 |
engrailed homeobox 2 |
affects response to substance |
ISO |
EN2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of ENO1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ENTPD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
affects response to substance |
ISO |
EPB41L3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
Etoposide results in increased expression of EPHX1 mRNA |
CTD |
PMID:21382384 PMID:25270620 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein]; EPO protein results in increased susceptibility to [Organoplatinum Compounds co-treated with Etoposide] |
CTD |
PMID:18403296 PMID:29069929 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression decreases response to substance affects response to substance |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide] Etoposide results in decreased expression of ERBB2 mRNA ERBB2 protein results in decreased susceptibility to Etoposide; ERBB2 results in decreased susceptibility to Etoposide ERBB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:10327070 PMID:15228094 PMID:21712253 PMID:25866362 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
affects response to substance decreases expression |
ISO |
ERBB3 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of ERBB3 mRNA |
CTD |
PMID:15228094 PMID:16217747 PMID:29397400 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ERBB4 mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Etoposide results in increased expression of EREG mRNA |
CTD |
PMID:15228094 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
affects response to substance |
ISO |
ERVFRD-1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases response to substance multiple interactions |
ISO |
ESR2 protein results in increased susceptibility to Etoposide TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide] |
CTD |
PMID:20623183 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrp1 |
epithelial splicing regulatory protein 1 |
affects response to substance |
ISO |
ESRP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Etoposide inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]; Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions increases expression |
ISO |
DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein] |
CTD |
PMID:30177839 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
increases response to substance increases mutagenesis |
ISO |
ETV6 gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of ETV6 gene |
CTD |
PMID:15217836 PMID:28624474 |
|
NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Exoc4 |
exocyst complex component 4 |
increases expression |
ISO |
Etoposide results in increased expression of EXOC4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:61,807,706...62,584,316
Ensembl chr 4:61,807,761...62,585,723
|
|
G |
F11r |
F11 receptor |
increases expression |
ISO |
Etoposide results in increased expression of F11R mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
affects response to substance |
ISO |
F2R protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Etoposide results in increased expression of F3 mRNA |
CTD |
PMID:12542493 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fads3 |
fatty acid desaturase 3 |
increases expression |
ISO |
Etoposide results in increased expression of FADS3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:206,685,667...206,702,538
Ensembl chr 1:206,685,894...206,704,769
|
|
G |
Fam171a1 |
family with sequence similarity 171, member A1 |
affects response to substance |
ISO |
FAM171A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:75,024,582...75,148,348
Ensembl chr17:75,024,575...75,150,255
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein]; Etoposide results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein] Etoposide results in increased expression of FAS mRNA Etoposide results in increased expression of FAS mRNA; Etoposide results in increased expression of FAS protein |
CTD |
PMID:12513834 PMID:15475000 PMID:16192531 PMID:29397400 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression increases activity |
ISO |
[linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; Nitric Oxide inhibits the reaction [Etoposide results in increased activity of FASLG promoter] Etoposide results in increased expression of FASL mRNA |
CTD |
PMID:10811113 PMID:12513834 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Etoposide results in increased expression of FASN mRNA |
CTD |
PMID:17089011 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbl |
fibrillarin |
affects localization |
ISO |
Etoposide analog affects the localization of FBL protein |
CTD |
PMID:10942594 |
|
NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects response to substance |
ISO |
FDFT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
Etoposide results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
affects response to substance |
ISO |
FHL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of FHL2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Flnc |
filamin C |
increases expression |
ISO |
Etoposide results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases response to substance increases expression multiple interactions |
EXP ISO |
FOS protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of FOS [Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA; Acetylcysteine inhibits the reaction [Etoposide results in increased expression of FOS] |
CTD |
PMID:10711420 PMID:18314485 PMID:23824011 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Etoposide results in increased expression of FOSL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxf2 |
forkhead box F2 |
affects response to substance |
ISO |
FOXF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:32,835,730...32,842,547
Ensembl chr17:32,836,777...32,842,176
|
|
G |
Foxj2 |
forkhead box J2 |
decreases expression |
ISO |
Etoposide results in decreased expression of FOXJ2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:156,047,043...156,073,540
Ensembl chr 4:156,046,969...156,073,518
|
|
G |
Foxo1 |
forkhead box O1 |
increases phosphorylation multiple interactions |
ISO |
Etoposide results in increased phosphorylation of FOXO1 protein wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO1 protein] |
CTD |
PMID:17935137 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
increases phosphorylation increases response to substance multiple interactions |
ISO |
Etoposide results in increased phosphorylation of FOXO3 protein FOXO3 protein results in increased susceptibility to Etoposide [FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; Wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:17935137 PMID:19211844 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions increases expression |
ISO |
HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA] |
CTD |
PMID:20980392 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of FTL mRNA; Etoposide results in increased expression of FTL protein 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in increased expression of FTL protein]; ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein]; Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein]; FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein]; FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:33969609 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Fut8 |
fucosyltransferase 8 |
affects response to substance |
ISO |
FUT8 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:95,949,246...96,176,677
Ensembl chr 6:95,949,991...96,176,677
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
affects response to substance decreases expression |
ISO |
FYN protein affects the susceptibility to Etoposide Etoposide results in decreased expression of FYN mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of FZD1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G |
Fzd5 |
frizzled class receptor 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of FZD5 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases response to substance multiple interactions increases expression |
ISO |
GADD45A protein results in increased susceptibility to Etoposide IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein] Etoposide results in increased expression of GADD45A mRNA; Etoposide results in increased expression of GADD45A protein |
CTD |
PMID:19003803 PMID:21527772 PMID:29397400 PMID:30177839 PMID:31542801 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Ganab |
glucosidase II alpha subunit |
multiple interactions decreases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of GANAB protein Etoposide results in decreased expression of GANAB protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
Etoposide results in increased expression of GAPDH protein |
CTD |
PMID:29733421 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10900222 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10900222 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions increases expression |
ISO |
Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA] [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of GDF15 mRNA; Etoposide results in increased expression of GDF15 protein |
CTD |
PMID:11895857 PMID:16120219 PMID:24211769 PMID:29397400 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases response to substance |
ISO |
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Tetradecanoylphorbol Acetate affects the reaction [GJA1 protein results in increased susceptibility to Etoposide] |
CTD |
PMID:23978459 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of GJA5 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:184,602,407...184,621,952
Ensembl chr 2:184,564,475...184,621,952
|
|
G |
Gls2 |
glutaminase 2 |
increases expression |
ISO |
Etoposide results in increased expression of GLS2 mRNA |
CTD |
PMID:21527772 PMID:29397400 |
|
NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426
|
|
G |
Gpihbp1 |
glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of GPIHBP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:107,285,584...107,288,702
Ensembl chr 7:107,285,654...107,288,702
|
|
G |
Gpm6b |
glycoprotein m6b |
affects response to substance |
ISO |
GPM6B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:28,057,788...28,204,409
Ensembl chr X:28,059,450...28,204,211
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
ISO |
Etoposide results in increased expression of GPNMB mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
affects response to substance |
ISO |
GPR37 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:54,138,870...54,161,001
|
|
G |
Gpsm2 |
G-protein signaling modulator 2 |
affects response to substance |
ISO |
GPSM2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Etoposide results in increased expression of GPX1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Etoposide results in increased expression of GPX3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
increases expression |
ISO |
Etoposide results in increased expression of GRIA3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
decreases expression |
ISO |
Etoposide results in decreased expression of GRPEL1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr14:74,292,023...74,298,243
Ensembl chr14:74,292,023...74,298,200
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases activity |
ISO |
BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein] [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of GSK3B protein |
CTD |
PMID:19408126 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects response to substance |
ISO |
GSTM1 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:15713801 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
affects response to substance |
ISO |
GSTM4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases response to substance affects response to substance |
ISO |
Curcumin inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Sulfinpyrazone inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; verlukast inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide] GSTP1 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:10900222 PMID:12969965 PMID:15999103 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
affects response to substance |
ISO |
GSTT2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression decreases response to substance increases phosphorylation |
ISO EXP |
Celecoxib inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; nimesulide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; pifithrin promotes the reaction [Etoposide results in increased expression of H2AX protein] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide results in increased expression of H2AX protein]; RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein]; TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione inhibits the reaction [Etoposide results in increased expression of H2AX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Razoxane inhibits the reaction [Etoposide results in increased expression of H2AX protein] H2AX protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of H2AX protein; Etoposide results in increased expression of H2AX protein modified form |
CTD |
PMID:17875725 PMID:20643100 PMID:20978201 PMID:21555580 PMID:21745461 PMID:22302033 PMID:25078064 PMID:26259609 PMID:28343997 PMID:32482060 PMID:33823233 PMID:34510228 PMID:35690182 PMID:37451322 More...
|
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hal |
histidine ammonia lyase |
decreases expression |
ISO |
Etoposide results in decreased expression of HAL mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of HAMP mRNA Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25270620 PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Etoposide results in increased expression of HBEGF mRNA |
CTD |
PMID:15228094 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of HBP1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787
|
|
G |
Hdac4 |
histone deacetylase 4 |
affects response to substance |
ISO |
HDAC4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
|
|
G |
Heph |
hephaestin |
affects response to substance |
ISO |
HEPH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980
|
|
G |
Hic1 |
HIC ZBTB transcriptional repressor 1 |
multiple interactions increases expression |
ISO |
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter] |
CTD |
PMID:19491197 |
|
NCBI chr10:60,014,520...60,019,475
Ensembl chr10:60,011,528...60,019,475
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; HIF1A mutant form inhibits the reaction [Oxygen deficiency results in decreased susceptibility to Etoposide]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:23144690 PMID:33969609 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hipk2 |
homeodomain interacting protein kinase 2 |
increases activity multiple interactions decreases response to substance |
ISO |
Etoposide results in increased activity of HIPK2 protein HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein]; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] HIPK2 results in decreased susceptibility to Etoposide HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA] |
CTD |
PMID:20573984 PMID:20980392 |
|
NCBI chr 4:67,439,327...67,619,223
Ensembl chr 4:67,440,501...67,619,223
|
|
G |
Hmces |
5-hydroxymethylcytosine binding, ES cell specific |
decreases expression |
ISO |
Etoposide results in decreased expression of HMCES mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:120,392,812...120,415,616
Ensembl chr 4:120,366,542...120,415,616
|
|
G |
Hmg20b |
high mobility group 20 B |
affects response to substance |
ISO |
HMG20B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:8,368,934...8,373,650
Ensembl chr 7:8,368,990...8,373,640
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
affects response to substance |
ISO |
HMGA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmgb1 |
high mobility group box 1 |
increases secretion decreases response to substance |
ISO |
Etoposide results in increased secretion of HMGB1 protein HMGB1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:27807322 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
decreases expression |
ISO |
Etoposide results in decreased expression of HNRNPH2 protein |
CTD |
PMID:29733421 |
|
NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hoxa5 |
homeo box A5 |
affects response to substance |
ISO |
HOXA5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90AA1 protein |
CTD |
PMID:24478030 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90B1 protein |
CTD |
PMID:24478030 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
affects response to substance |
ISO |
HSPA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
ISO |
Etoposide results in increased expression of HSPE1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
affects response to substance increases response to substance multiple interactions |
ISO |
HTATIP2 protein affects the susceptibility to Etoposide HTATIP2 protein results in increased susceptibility to Etoposide HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein] |
CTD |
PMID:16217747 PMID:16799960 |
|
NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
|
|
G |
Htr4 |
5-hydroxytryptamine receptor 4 |
affects response to substance |
ISO |
HTR4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:55,765,981...55,949,921
Ensembl chr18:55,766,725...55,949,321
|
|
G |
Ier5 |
immediate early response 5 |
increases expression |
ISO |
Etoposide results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
affects response to substance |
ISO |
IFITM1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
|
|
G |
Igdcc4 |
immunoglobulin superfamily, DCC subclass, member 4 |
increases expression |
ISO |
Etoposide results in increased expression of IGDCC4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:65,621,893...65,657,651
Ensembl chr 8:65,621,897...65,657,648
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
affects response to substance |
ISO |
IGF1R protein affects the susceptibility to Etoposide |
CTD |
PMID:15499378 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
affects response to substance |
ISO |
IGFBP7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
|
|
G |
Igsf11 |
immunoglobulin superfamily, member 11 |
decreases expression |
ISO |
Etoposide results in decreased expression of IGSF11 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:61,733,139...61,884,059
Ensembl chr11:61,733,144...61,868,348
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
affects response to substance multiple interactions decreases expression |
ISO |
IKBKB protein affects the susceptibility to Etoposide DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein] |
CTD |
PMID:20159942 PMID:30177839 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Etoposide results in increased expression of IL1B mRNA |
CTD |
PMID:18523641 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
decreases response to substance multiple interactions |
ISO |
IL4 protein results in decreased susceptibility to Etoposide [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10620629 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO EXP |
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased expression of IL6 mRNA]; (4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased secretion of IL6 protein] Etoposide results in increased expression of IL6 mRNA; Etoposide results in increased expression of IL6 protein |
CTD |
PMID:15135310 PMID:17003255 PMID:18523641 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inka2 |
inka box actin regulator 2 |
increases expression |
ISO |
Etoposide results in increased expression of INKA2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642
|
|
G |
Insig1 |
insulin induced gene 1 |
affects response to substance |
ISO |
INSIG1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Ints15 |
integrator complex subunit 15 |
decreases expression |
ISO |
Etoposide results in decreased expression of INTS15 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:11,245,045...11,260,170
Ensembl chr12:11,245,842...11,260,166
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions decreases expression |
ISO |
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of IREB2 protein] Etoposide results in decreased expression of IREB2 mRNA; Etoposide results in decreased expression of IREB2 protein |
CTD |
PMID:33969609 |
|
NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611
|
|
G |
Irs2 |
insulin receptor substrate 2 |
affects response to substance |
ISO |
IRS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Irx4 |
iroquois homeobox 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of IRX4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
ISO |
Etoposide results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Isg20 |
interferon stimulated exonuclease gene 20 |
affects response to substance |
ISO |
ISG20 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:132,829,303...132,837,027
Ensembl chr 1:132,815,123...132,837,027
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ISG20L2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
|
|
G |
Itga2b |
integrin subunit alpha 2b |
increases expression |
ISO |
Etoposide results in increased expression of ITGA2B mRNA |
CTD |
PMID:21527772 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itgb3 |
integrin subunit beta 3 |
increases response to substance |
ISO |
ITGB3 protein results in increased susceptibility to Etoposide |
CTD |
PMID:21332719 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
affects response to substance |
ISO |
ITPR1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA |
CTD |
PMID:10711420 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnab2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
affects response to substance |
ISO |
KCNAB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243
|
|
G |
Kcne3 |
potassium voltage-gated channel subfamily E regulatory subunit 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of KCNE3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:154,523,903...154,530,865
Ensembl chr 1:154,523,830...154,532,020
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of KCNN2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases response to substance multiple interactions increases response to substance |
ISO |
KEAP1 protein results in decreased susceptibility to Etoposide KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein] KEAP1 mRNA results in increased susceptibility to Etoposide |
CTD |
PMID:22684020 PMID:26708503 PMID:27982581 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kif1a |
kinesin family member 1A |
increases expression |
ISO |
Etoposide results in increased expression of KIF1A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
Etoposide results in decreased expression of KIF20A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif23 |
kinesin family member 23 |
decreases expression |
ISO |
Etoposide results in decreased expression of KIF23 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions increases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of KIT protein Etoposide results in increased expression of KIT protein |
CTD |
PMID:29733421 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of KLF4 mRNA; Etoposide results in increased expression of KLF4 protein FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein] |
CTD |
PMID:33969609 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf5 |
KLF transcription factor 5 |
increases expression |
ISO |
Etoposide results in increased expression of KLF5 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klf6 |
KLF transcription factor 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of KLF6 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klhl26 |
kelch-like family member 26 |
increases expression |
ISO |
Etoposide results in increased expression of KLHL26 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:18,952,123...18,977,328
Ensembl chr16:18,952,234...18,977,328
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA] |
CTD |
PMID:20601956 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
increases response to substance increases mutagenesis increases cleavage |
ISO |
KMT2A gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of KMT2A gene Etoposide results in increased cleavage of KMT2A gene |
CTD |
PMID:14712291 PMID:24086652 PMID:28624474 |
|
NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Etoposide results in increased expression of KRT19 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt80 |
keratin 80 |
increases expression |
ISO |
Etoposide results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:132,463,216...132,485,134
Ensembl chr 7:132,463,218...132,485,508
|
|
G |
Kynu |
kynureninase |
affects response to substance |
ISO |
KYNU protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lancl1 |
LanC like glutathione S-transferase 1 |
affects response to substance |
ISO |
LANCL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:68,515,052...68,548,646
Ensembl chr 9:68,518,574...68,548,628
|
|
G |
Lap3 |
leucine aminopeptidase 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of LAP3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:65,608,375...65,627,359
Ensembl chr14:65,608,376...65,627,359
|
|
G |
Lcn2 |
lipocalin 2 |
increases response to substance |
EXP |
LCN2 protein results in increased susceptibility to Etoposide |
CTD |
PMID:19860839 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldb3 |
LIM domain binding 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of LDB3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:9,855,768...9,920,108
Ensembl chr16:9,855,927...9,918,532
|
|
G |
Lgals3 |
galectin 3 |
affects response to substance |
ISO |
LGALS3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lgals7 |
galectin 7 |
increases expression |
ISO |
Etoposide results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:84,148,612...84,152,016
Ensembl chr 1:84,150,252...84,152,015
|
|
G |
Lhx1 |
LIM homeobox 1 |
multiple interactions decreases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of LHX1 mRNA Etoposide results in decreased expression of LHX1 mRNA |
CTD |
PMID:29733421 |
|
NCBI chr10:69,396,829...69,403,617
Ensembl chr10:69,396,829...69,403,617
|
|
G |
Lhx2 |
LIM homeobox 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of LHX2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Etoposide results in increased expression of LIF mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Limch1 |
LIM and calponin homology domains 1 |
affects response to substance |
ISO |
LIMCH1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191
|
|
G |
Lipa |
lipase A, lysosomal acid type |
affects response to substance |
ISO |
LIPA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633
|
|
G |
Lrrc47 |
leucine rich repeat containing 47 |
decreases expression |
ISO |
Etoposide results in decreased expression of LRRC47 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:164,570,539...164,580,174
Ensembl chr 5:164,570,435...164,580,174
|
|
G |
Ltbr |
lymphotoxin beta receptor |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of LTBR mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr 4:158,108,884...158,115,339
Ensembl chr 4:158,108,886...158,121,539
|
|
G |
Lxn |
latexin |
increases response to substance |
ISO |
LXN protein results in increased susceptibility to Etoposide |
CTD |
PMID:25341047 |
|
NCBI chr 2:151,727,556...151,733,426
Ensembl chr 2:151,727,102...151,733,460
|
|
G |
Ly6e |
lymphocyte antigen 6 family member E |
affects response to substance |
ISO |
LY6E protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689
|
|
G |
Macf1 |
microtubule-actin crosslinking factor 1 |
affects response to substance |
ISO |
MACF1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905
|
|
G |
Man2b1 |
mannosidase, alpha, class 2B, member 1 |
increases expression |
ISO |
Etoposide results in increased expression of MAN2B1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:23,055,092...23,074,398
Ensembl chr19:23,055,097...23,074,389
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
increases expression |
ISO |
Etoposide results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Map7 |
microtubule-associated protein 7 |
affects response to substance |
ISO |
MAP7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:14,910,433...15,037,574
Ensembl chr 1:14,910,551...15,037,574
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16014620 PMID:19720055 PMID:26046675 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk12 |
mitogen-activated protein kinase 12 |
increases activity affects response to substance multiple interactions |
ISO |
Etoposide results in increased activity of MAPK12 protein MAPK12 protein affects the susceptibility to Etoposide [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide |
CTD |
PMID:21878638 |
|
NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16014620 PMID:19720055 PMID:26046675 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
multiple interactions increases phosphorylation |
ISO |
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased phosphorylation of MAPKAPK2 protein] |
CTD |
PMID:17003255 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Matn2 |
matrilin 2 |
affects response to substance |
ISO |
MATN2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113
|
|
G |
Mbp |
myelin basic protein |
affects response to substance |
ISO |
MBP protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcam |
melanoma cell adhesion molecule |
increases expression |
ISO |
Etoposide results in increased expression of MCAM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression |
ISO |
wortmannin promotes the reaction [Etoposide results in decreased expression of MCL1 protein] |
CTD |
PMID:17935137 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcm10 |
minichromosome maintenance 10 replication initiation factor |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM10 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM2 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM6 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM7 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mcm8 |
minichromosome maintenance 8 homologous recombination repair factor |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM8 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008
|
|
G |
Mdfic |
MyoD family inhibitor domain containing |
affects response to substance |
ISO |
MDFIC protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:43,972,310...44,052,162
Ensembl chr 4:43,972,507...44,052,161
|
|
G |
Mdh2 |
malate dehydrogenase 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of MDH2 protein |
CTD |
PMID:29733421 |
|
NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions decreases expression increases phosphorylation increases expression decreases response to substance |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of MDM2 protein]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; Wortmannin promotes the reaction [Etoposide results in increased phosphorylation of MDM2 protein] Etoposide results in decreased expression of MDM2 protein Etoposide results in increased expression of MDM2 mRNA; Etoposide results in increased expression of MDM2 protein; Etoposide results in increased expression of MDM2 protein modified form Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of MDM2 protein] MDM2 promoter SNP results in decreased susceptibility to Etoposide |
CTD |
PMID:15459018 PMID:16120219 PMID:17575151 PMID:17935137 PMID:18096571 PMID:25078064 PMID:25744307 PMID:26259609 PMID:30177839 PMID:31542801 More...
|
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Me2 |
malic enzyme 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ME2 protein |
CTD |
PMID:29733421 |
|
NCBI chr18:67,350,833...67,400,987
Ensembl chr18:67,355,795...67,400,987
|
|
G |
Mir135b |
microRNA 135b |
increases expression |
ISO |
Etoposide results in increased expression of MIR135B mRNA |
CTD |
PMID:27570640 |
|
NCBI chr13:43,638,857...43,638,953
Ensembl chr13:43,638,857...43,638,953
|
|
G |
Mir139 |
microRNA 139 |
increases expression |
ISO |
Etoposide results in increased expression of MIR139 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:155,878,828...155,878,895
Ensembl chr 1:155,878,825...155,878,902
|
|
G |
Mir196b |
microRNA 196b |
increases expression |
ISO |
Etoposide results in increased expression of MIR196B mRNA |
CTD |
PMID:27570640 |
|
NCBI chr 4:81,330,487...81,330,571
Ensembl chr 4:81,330,487...81,330,571
|
|
G |
Mir34c |
microRNA 34c |
increases expression |
ISO |
Etoposide results in increased expression of MIR34C mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:51,409,726...51,409,802
Ensembl chr 8:51,409,726...51,409,802
|
|
G |
Mlana |
melan-A |
affects response to substance |
ISO |
MLANA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:227,469,537...227,483,343
Ensembl chr 1:227,469,537...227,483,343
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
affects response to substance |
ISO |
MLLT11 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of MMP1 protein pifithrin inhibits the reaction [Etoposide results in decreased expression of MMP1 protein] |
CTD |
PMID:18557930 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mocos |
molybdenum cofactor sulfurase |
affects response to substance |
ISO |
MOCOS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:15,931,659...15,977,415
Ensembl chr18:15,931,654...15,977,187
|
|
G |
Mpo |
myeloperoxidase |
increases metabolic processing |
ISO |
MPO protein results in increased metabolism of Etoposide |
CTD |
PMID:16841962 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mpzl1 |
myelin protein zero-like 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MPZL1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
increases expression affects expression |
ISO |
Etoposide results in increased expression of MR1 mRNA Etoposide affects the expression of MR1 mRNA |
CTD |
PMID:21527772 PMID:25811541 |
|
NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970
|
|
G |
Mras |
muscle RAS oncogene homolog |
decreases expression |
ISO |
Etoposide results in decreased expression of MRAS mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MRC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Mrm2 |
mitochondrial rRNA methyltransferase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MRM2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:14,309,556...14,314,759
Ensembl chr12:14,251,941...14,314,118
|
|
G |
Msc |
musculin |
decreases expression |
ISO |
Etoposide results in decreased expression of MSC mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:4,547,335...4,553,206
Ensembl chr 5:4,547,405...4,553,203
|
|
G |
Msh6 |
mutS homolog 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of MSH6 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956
|
|
G |
Mt-nd4 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 |
increases expression |
ISO |
Etoposide results in increased expression of ND4 mRNA |
CTD |
PMID:26259609 |
|
NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537
|
|
G |
Mt2A |
metallothionein 2A |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of MT2A protein XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein] |
CTD |
PMID:28507149 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Etoposide results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of MTOR protein |
CTD |
PMID:27769712 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mtus1 |
microtubule associated scaffold protein 1 |
affects response to substance |
ISO |
MTUS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:51,202,497...51,347,794
Ensembl chr16:51,253,562...51,347,793
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
affects response to substance |
ISO |
MXI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression increases response to substance multiple interactions |
ISO |
Etoposide results in decreased expression of MYC; Etoposide results in decreased expression of MYC mRNA MYC protein results in increased susceptibility to Etoposide MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] |
CTD |
PMID:9454737 PMID:21324178 PMID:21527772 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mycn |
MYCN proto-oncogene, bHLH transcription factor |
multiple interactions decreases response to substance |
ISO |
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide MYCN protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10348353 |
|
NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590
|
|
G |
Myh7 |
myosin heavy chain 7 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYH7 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl2 |
myosin light chain 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYL2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983
|
|
G |
Myl3 |
myosin light chain 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYL3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:110,738,669...110,744,814
Ensembl chr 8:110,738,661...110,744,816
|
|
G |
Myom2 |
myomesin 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYOM2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:74,520,148...74,592,658
Ensembl chr16:74,520,157...74,592,772
|
|
G |
Myot |
myotilin |
increases expression |
ISO |
Etoposide results in increased expression of MYOT mRNA |
CTD |
PMID:29397400 |
|
NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841
|
|
G |
Myt1 |
myelin transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYT1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:168,890,466...168,950,341
Ensembl chr 3:168,886,089...168,950,341
|
|
G |
Nabp2 |
nucleic acid binding protein 2 |
multiple interactions increases acetylation |
ISO |
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Etoposide results in increased acetylation of NABP2 protein] |
CTD |
PMID:26170237 |
|
NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027
|
|
G |
Nap1l1 |
nucleosome assembly protein 1-like 1 |
affects response to substance |
ISO |
NAP1L1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593
|
|
G |
Nck2 |
NCK adaptor protein 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:45,713,979...45,840,330
Ensembl chr 9:45,714,883...45,840,307
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NECTIN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:79,372,123...79,407,379
Ensembl chr 1:79,372,119...79,407,360
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated 9 |
affects response to substance |
ISO |
NEDD9 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019
|
|
G |
Nek2 |
NIMA-related kinase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NEK2 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases response to substance multiple interactions |
ISO |
NFE2L2 mRNA results in decreased susceptibility to Etoposide; NFE2L2 protein results in decreased susceptibility to Etoposide NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:26708503 PMID:27982581 PMID:33148531 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:23396362 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases degradation |
ISO |
wortmannin inhibits the reaction [Etoposide results in increased degradation of NFKBIA protein] |
CTD |
PMID:12637521 PMID:17935137 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nherf1 |
NHERF family PDZ scaffold protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of NHERF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:100,403,189...100,420,290
Ensembl chr10:100,403,069...100,420,598
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
affects response to substance |
ISO |
NIBAN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
|
|
G |
Nit2 |
nitrilase family, member 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of NIT2 protein |
CTD |
PMID:29733421 |
|
NCBI chr11:43,363,839...43,378,713
Ensembl chr11:43,363,985...43,375,024
|
|
G |
Nmt2 |
N-myristoyltransferase 2 |
affects response to substance |
ISO |
NMT2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:74,917,833...74,964,788
Ensembl chr17:74,917,833...74,961,080
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP ISO |
Etoposide results in increased expression of NOS2 mRNA Etoposide results in increased expression of NOS2 protein |
CTD |
PMID:15135310 PMID:26259609 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npas1 |
neuronal PAS domain protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of NPAS1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:77,167,375...77,187,887
Ensembl chr 1:77,167,381...77,186,762
|
|
G |
Npnt |
nephronectin |
increases expression |
ISO |
Etoposide results in increased expression of NPNT mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
affects response to substance increases expression multiple interactions |
ISO |
NQO1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NQO1 mRNA HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] |
CTD |
PMID:16217747 PMID:20980392 PMID:29397400 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of NR0B1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
affects localization affects response to substance multiple interactions |
ISO |
Etoposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Etoposide Etoposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA]; NR1H2 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] |
CTD |
PMID:25914138 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions affects response to substance increases expression |
ISO |
Etoposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Etoposide results in increased expression of and affects the localization of NR1H3 protein; NR1H3 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] NR1H3 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NR1H3 mRNA |
CTD |
PMID:25914138 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects response to substance multiple interactions increases activity |
ISO |
NR1I2 protein affects the susceptibility to Etoposide [Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17279585 PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] |
CTD |
PMID:30818834 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrap |
nebulin-related anchoring protein |
decreases expression |
ISO |
Etoposide results in decreased expression of NRAP mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:255,350,113...255,427,693
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Etoposide results in increased expression of NRG1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
affects response to substance decreases expression |
ISO |
NRIP1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NRIP1 mRNA; Etoposide results in decreased expression of NRIP1 protein |
CTD |
PMID:16217747 PMID:25914138 |
|
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
affects response to substance decreases expression |
ISO |
NUPR1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NUPR1 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of OAT protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Oca2 |
OCA2 melanosomal transmembrane protein |
affects response to substance |
ISO |
OCA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:107,116,278...107,446,093
Ensembl chr 1:107,116,278...107,446,074
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of OGG1 mRNA wogonin inhibits the reaction [Etoposide results in decreased expression of OGG1 mRNA] |
CTD |
PMID:23872129 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
increases expression |
ISO |
Etoposide results in increased expression of P2RX7 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Pabpc1 |
poly(A) binding protein, cytoplasmic 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PABPC1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:67,777,438...67,789,731
Ensembl chr 7:67,777,381...67,789,744
|
|
G |
Palb2 |
partner and localizer of BRCA2 |
decreases expression |
ISO |
Etoposide results in decreased expression of PALB2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:176,665,076...176,689,053
Ensembl chr 1:176,665,076...176,688,990
|
|
G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
increases expression |
ISO |
Etoposide results in increased expression of PAPSS2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions increases degradation |
EXP ISO |
Etoposide results in increased cleavage of PARP1 protein 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein]; Nicotine inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein] Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein] |
CTD |
PMID:8840993 PMID:9454737 PMID:12690110 PMID:16014620 PMID:16545138 PMID:16799960 PMID:16807353 PMID:16844113 PMID:17516866 PMID:17935137 PMID:20457658 PMID:21801448 PMID:25447644 PMID:26259609 PMID:28507149 PMID:30890322 PMID:33148531 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
affects response to substance |
ISO |
PBK protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcbp2 |
poly(rC) binding protein 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PCBP2 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:133,605,375...133,631,312
Ensembl chr 7:133,605,573...133,629,863
|
|
G |
Pcbp4 |
poly(rC) binding protein 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of PCBP4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:107,092,688...107,103,276
Ensembl chr 8:107,093,013...107,103,276
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
decreases expression |
ISO |
Etoposide results in decreased expression of PCK2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|
G |
Pde2a |
phosphodiesterase 2A |
decreases expression |
ISO |
Etoposide results in decreased expression of PDE2A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434
|
|
G |
Pde4b |
phosphodiesterase 4B |
affects response to substance |
ISO |
PDE4B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pdgfc |
platelet derived growth factor C |
affects response to substance |
ISO |
PDGFC protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:166,316,870...166,493,449
Ensembl chr 2:166,316,803...166,493,433
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of PDIA3 protein |
CTD |
PMID:24478030 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PDK1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Etoposide results in increased expression of PDK4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdlim3 |
PDZ and LIM domain 3 |
increases expression |
ISO |
Etoposide results in increased expression of PDLIM3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:46,352,460...46,383,680
Ensembl chr16:46,352,467...46,383,657
|
|
G |
Pelo |
pelota mRNA surveillance and ribosome rescue factor |
decreases expression |
ISO |
Etoposide results in decreased expression of PELO mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:46,797,853...46,799,621
Ensembl chr 2:46,797,853...46,799,746
|
|
G |
Perp |
p53 apoptosis effector related to PMP22 |
increases expression |
ISO |
Etoposide results in increased expression of PERP mRNA |
CTD |
PMID:21382384 PMID:25270620 |
|
NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
affects response to substance |
ISO |
PHGDH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
ISO |
Etoposide results in increased expression of PHLDA3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
multiple interactions |
ISO |
[Cisplatin co-treated with Etoposide] results in increased mutagenesis of PIGA |
CTD |
PMID:21826740 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
affects response to substance |
ISO |
PIP5K1B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:221,907,220...222,183,672
Ensembl chr 1:221,914,159...222,183,672
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
Etoposide results in increased expression of PLAU mRNA |
CTD |
PMID:21527772 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PLK1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Etoposide results in increased expression of PLK2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plk3 |
polo-like kinase 3 |
increases expression |
ISO |
Etoposide results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317
|
|
G |
Plp1 |
proteolipid protein 1 |
affects response to substance |
ISO |
PLP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Plpp2 |
phospholipid phosphatase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of PLPP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:10,175,918...10,184,032
Ensembl chr 7:10,175,948...10,184,071
|
|
G |
Pm20d1 |
peptidase M20 domain containing 1 |
increases expression |
ISO |
Etoposide results in increased expression of PM20D1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr13:43,237,954...43,259,999
Ensembl chr13:43,237,971...43,259,999
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:21801448 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pmel |
premelanosome protein |
affects response to substance |
ISO |
PMEL protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746
|
|
G |
Pmp2 |
peripheral myelin protein 2 |
affects response to substance |
ISO |
PMP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:91,611,334...91,615,252
Ensembl chr 2:91,611,334...91,615,252
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
affects response to substance |
ISO |
PMP22 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Polq |
DNA polymerase theta |
decreases response to substance |
ISO |
POLQ results in decreased susceptibility to Etoposide |
CTD |
PMID:21883722 |
|
NCBI chr11:63,673,796...63,775,905
Ensembl chr11:63,673,816...63,775,878
|
|
G |
Polr1h |
RNA polymerase I subunit H |
decreases response to substance multiple interactions |
ISO |
POLR1H protein results in decreased susceptibility to Etoposide Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:14726695 |
|
NCBI chr20:1,594,936...1,598,854
Ensembl chr20:1,594,936...1,598,854
|
|
G |
Postn |
periostin |
increases expression |
ISO |
Etoposide results in increased expression of POSTN mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
Etoposide results in increased expression of POU5F1 mRNA; Etoposide results in increased expression of POU5F1 protein |
CTD |
PMID:33969609 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of PPARGC1A mRNA Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:26259609 PMID:30818834 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
increases expression |
ISO |
Etoposide results in increased expression of PPARGC1B mRNA |
CTD |
PMID:26259609 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
increases expression |
ISO |
Etoposide results in increased expression of PPM1D protein |
CTD |
PMID:25078064 |
|
NCBI chr10:70,172,603...70,208,607
Ensembl chr10:70,172,603...70,208,607
|
|
G |
Ppp1r13l |
protein phosphatase 1, regulatory subunit 13 like |
increases expression multiple interactions decreases response to substance |
ISO |
Etoposide results in increased expression of PPP1R13L mRNA Etoposide results in increased expression of and results in increased localization of PPP1R13L protein PPP1R13L results in decreased susceptibility to Etoposide |
CTD |
PMID:17570360 PMID:19299014 |
|
NCBI chr 1:79,010,997...79,030,714
Ensembl chr 1:79,011,745...79,030,712
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prdx1 |
peroxiredoxin 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PRDX1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prkab1 |
protein kinase AMP-activated non-catalytic subunit beta 1 |
increases expression |
ISO |
Etoposide results in increased expression of PRKAB1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
Etoposide results in increased cleavage of and results in increased activity of PRKCD protein |
CTD |
PMID:19662097 |